Showing results (61-70 of 203) with videos related to
Sort By:
Pageof 21
Oncogene|November 23, 2005
Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1C Britschgi, M Rizzi, T J Grob, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1997
Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK)M Fopp, M F Fey, M Bacchi, et al.Leukemia & Lymphoma|October 24, 2000
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemiaT Pabst, U R Peters, M Tinguely, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK)D C Betticher, D Ratschiller, S F Hsu Schmitz, et al.Schweizerische Medizinische Wochenschrift|May 18, 1996
[Chemotherapy of gastrointestinal carcinomas and non-small-cell pulmonary carcinoma: a controversy]M F Fey, C Sauter, P AlbertoInternational Journal of Cancer|August 30, 2000
Differential expression of p73 splice variants and protein in benign and malignant ovarian tumoursD Zwahlen, M P Tschan, T J Grob, et al.Oncogene|December 5, 1998
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpressionS Vonlanthen, J Heighway, M P Tschan, et al.Cell Death and Differentiation|December 26, 2001
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53T J Grob, U Novak, C Maisse, et al.Schweizerische Medizinische Wochenschrift|March 18, 1995
[Diagnosis and therapy of multiple myeloma: current aspects]D C Betticher, T Cerny, M F FeyTherapeutische Umschau. Revue Therapeutique|March 17, 2004
[Myelodysplastic syndromes--an overview for the practitioner]M Solenthaler, A ToblerPageof 21